Related Experiment Video
Updated: Jul 13, 2026
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
Innovative approaches to COVID-19 medical countermeasure development
Gavin H Harris1, Amesh A Adalja2
1Emory University School of Medicine, Department of Medicine, Atlanta, GA, USA.
Background:
The COVID-19 pandemic, while unfortunately notable for immense strain and death throughout the world, has also shown great promise in the development of medical countermeasures. As the global scientific community shifted almost entirely towards vaccines, diagnostics and therapeutics, new trial designs most significantly adaptive platform trials, began to be used with greater speed and broader reach. These designs allowed for deploying and investigating new therapeutics, repurposing currently existing therapeutics and flexibly removing or adding additional medications as data appeared in real-time. Moreover, public-private sector partnering occurred at a level not seen before, contributing greatly to the rapid development and deployment of vaccines.
Objectives:
To provide a brief overview of the advances in preventative and therapeutic medical countermeasure development for COVID-19.
Methods:
A narrative review of relevant major medical countermeasure trials was conducted using the date range February 2020-December 2022, representing the period of greatest productivity in research to investigate COVID-19.
Results:
Among the most influential trial designs are the adaptive platform designs, which have been applied to the development of initial COVID-19 antivirals, monoclonal antibodies, repurposing of existing immunomodulatory therapy and assisted in the disproof of ineffective medical therapies. Some of the most prominent examples include the REMAP-CAP, RECOVERY and TOGETHER trials.
Conclusions:
Adaptive platform trial designs hold great promise for utility in future pandemics and mass casualty events. Additionally, public-private sectoring is essential for rapid medical countermeasure development and should be further enhanced for future biopreparedness.
Insights
Adaptive platform trials accelerated the development of COVID-19 medical countermeasures. These innovative trial designs, alongside public-private partnerships, are crucial for future pandemic preparedness.
Area of Science:
- Infectious Diseases
- Clinical Trials
- Public Health
Background:
- The COVID-19 pandemic spurred rapid advancements in medical countermeasures, including vaccines, diagnostics, and therapeutics.
- The crisis necessitated innovative approaches to clinical trial design and execution.
- Global collaboration significantly accelerated the development and deployment of critical medical interventions.
Approach:
- A narrative review of major COVID-19 medical countermeasure trials was conducted.
- The review covered the period of greatest research productivity from February 2020 to December 2022.
- Focus was placed on influential trial designs and their impact.
Key Points:
- Adaptive platform trials enabled rapid investigation and deployment of therapeutics, including antivirals and monoclonal antibodies.
- These designs facilitated the repurposing of existing therapies and the efficient disproval of ineffective treatments.
- Prominent examples include the REMAP-CAP, RECOVERY, and TOGETHER trials.
Conclusions:
- Adaptive platform trials demonstrate significant potential for future pandemics and mass casualty events.
- Public-private sector collaboration is vital for accelerating medical countermeasure development.
- Enhanced biopreparedness strategies should prioritize strengthening these partnerships.
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:29Microorganisms in Medicine and Therapeutics
01:28Antimicrobial Effectiveness
01:24Microbial Corrosion